Author:
Schran Horst F.,Tse Francis L.S.,Chang Cheng-Tao,Hunt Thomas L.,Saxe Michael A.,Ventura Daniel F.,Diserio Frank J.,Hendler Judith
Subject
Pharmacology (medical),Pharmacology
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults;Headache: The Journal of Head and Face Pain;2024-02-27
2. A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects;Headache: The Journal of Head and Face Pain;2020-04
3. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?;Expert Opinion on Pharmacotherapy;2010-11-17
4. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics;Current Medical Research and Opinion;2008-06-04
5. Safety and Pharmacokinetics of Dihydroergotamine Mesylate Administered Via a Novel (Tempo™) Inhaler;Headache: The Journal of Head and Face Pain;2007-12-28